Abstract:Background-Passive infusion of HLA antibodies has been implicated in transfusion reactions. A rapid, inexpensive method of screening blood donors for HLA antibodies might reduce the incidence of reactions. A high-throughput microbead-flow analyzer HLA antibody detection technique was compared with an ELISA method.
“…The Luminex assay was also used in two recent smaller studies of HLA alloimmunization in blood donors, both of which reported higher rates than what we observed at the 3SD cutoff but similar to our results at the NBG cutoff of 2.2 10,26. Powers et al tested 1027 women and 26 males with a history of transfusion.…”
Section: Discussionsupporting
confidence: 89%
“…These ELISA results are almost identical to the results of a larger study of 1043 donors reporting HLA antibodies in 9.8% of females and none in males 27. The most likely explanation for the high prevalence using microbead flow assays observed in the two smaller studies10,26 is that they used the manufacturer's suggested NBG cutoff of 2.2. We found similar results in our larger study when we used the same cutoffs.…”
Section: Discussionsupporting
confidence: 80%
“…They identified HLA antibodies in 25.4% of all female donors (vs. 17.3% at 3SD and 27.4% at NBG 2.2 in our study), 5.9% in never pregnant nor transfused women (vs. 1.7% at 3SD and 8.3% at NBG 2.2 in our study), and 12.0% of non-transfused males (vs. 1.0% at 3SD and 6.8% at NBG 2.2 in our study). A smaller study by Fadeyi et al26 also reported a higher prevalence of HLA antibodies in 96 apheresis donors; finding HLA antibodies in 56% of females and 35% of males. Fadeyi et al26 also tested each sample for HLA antibodies by ELISA and reported that 5/44 (9%) of women and 0/55 (0%) men were positive.…”
Section: Discussionmentioning
confidence: 88%
“…A smaller study by Fadeyi et al26 also reported a higher prevalence of HLA antibodies in 96 apheresis donors; finding HLA antibodies in 56% of females and 35% of males. Fadeyi et al26 also tested each sample for HLA antibodies by ELISA and reported that 5/44 (9%) of women and 0/55 (0%) men were positive. These ELISA results are almost identical to the results of a larger study of 1043 donors reporting HLA antibodies in 9.8% of females and none in males 27.…”
Background-Antibodies to human leukocyte antigens (HLA) in donated blood have been implicated as a cause of transfusion related acute lung injury (TRALI). A potential measure to reduce the risk of TRALI includes screening platelet apheresis donors for HLA antibodies. The prevalence of HLA antibodies and their relationship to previous transfusion or pregnancy in blood donors was determined.
“…The Luminex assay was also used in two recent smaller studies of HLA alloimmunization in blood donors, both of which reported higher rates than what we observed at the 3SD cutoff but similar to our results at the NBG cutoff of 2.2 10,26. Powers et al tested 1027 women and 26 males with a history of transfusion.…”
Section: Discussionsupporting
confidence: 89%
“…These ELISA results are almost identical to the results of a larger study of 1043 donors reporting HLA antibodies in 9.8% of females and none in males 27. The most likely explanation for the high prevalence using microbead flow assays observed in the two smaller studies10,26 is that they used the manufacturer's suggested NBG cutoff of 2.2. We found similar results in our larger study when we used the same cutoffs.…”
Section: Discussionsupporting
confidence: 80%
“…They identified HLA antibodies in 25.4% of all female donors (vs. 17.3% at 3SD and 27.4% at NBG 2.2 in our study), 5.9% in never pregnant nor transfused women (vs. 1.7% at 3SD and 8.3% at NBG 2.2 in our study), and 12.0% of non-transfused males (vs. 1.0% at 3SD and 6.8% at NBG 2.2 in our study). A smaller study by Fadeyi et al26 also reported a higher prevalence of HLA antibodies in 96 apheresis donors; finding HLA antibodies in 56% of females and 35% of males. Fadeyi et al26 also tested each sample for HLA antibodies by ELISA and reported that 5/44 (9%) of women and 0/55 (0%) men were positive.…”
Section: Discussionmentioning
confidence: 88%
“…A smaller study by Fadeyi et al26 also reported a higher prevalence of HLA antibodies in 96 apheresis donors; finding HLA antibodies in 56% of females and 35% of males. Fadeyi et al26 also tested each sample for HLA antibodies by ELISA and reported that 5/44 (9%) of women and 0/55 (0%) men were positive. These ELISA results are almost identical to the results of a larger study of 1043 donors reporting HLA antibodies in 9.8% of females and none in males 27.…”
Background-Antibodies to human leukocyte antigens (HLA) in donated blood have been implicated as a cause of transfusion related acute lung injury (TRALI). A potential measure to reduce the risk of TRALI includes screening platelet apheresis donors for HLA antibodies. The prevalence of HLA antibodies and their relationship to previous transfusion or pregnancy in blood donors was determined.
“…[20][21][22][23] These systems are generally more sensitive than LCA, and several commercial kits are currently available. 20,[24][25][26] Antibodies against human platelet antigens (HPAs) can also be generated in response to platelet transfusion. These antigens appear to be less immunogenic than HLA antigens, resulting in a lower frequency of HPA alloimmunization, which ranges from 0% to 2%, depending on the patient population.…”
• High, but not low to moderate, HLA antibody levels are associated with platelet refractoriness.In the Trial to Reduce Alloimmunization to Platelets (TRAP) study, 101 of 530 participants became refractory to platelet transfusions without evidence of HLA or human platelet antigen (HPA) antibodies. We used a more sensitive bead-based assay to detect and quantify HLA antibodies and a qualitative solid-phase enzyme-linked immunosorbet assay for HPA to determine whether low-level antibodies could predict refractoriness in longitudinal panels from 170 lymphocytotoxicity assay (LCA) 2 and 20 LCA Continuing Medical Education online This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and the American Society of Hematology. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at http://www.medscape.org/journal/blood; and (4) view/print certificate. For CME questions, see page 3299. Disclosures The authors, Associate Editor Mortimer Poncz, and CME questions author Charles P. Vega, Associate Professor and Residency Director, Department of Family Medicine, University of California-Irvine, declare no competing financial interests. Learning objectives Upon completion of this activity, participants will be able to:1. Describe alloimmunization due to HLA after platelet transfusion. 2. Analyze the significance of human platelet antigen (HPA) antibodies (Abs) in cases of alloimmunization after transfusion. 3. Evaluate the performance of newer tests for HLA Ab and HPA Ab. 4. Assess the role of HLA Ab and HPA Ab among patients refractory to treatment with platelet transfusions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.